Innate Pharma (IPHA) Expected to Announce Earnings on Wednesday

Posted by Brenda Bartman on May 12th, 2026

Innate Pharma (NASDAQ:IPHA – Get Free Report) is expected to be posting its Q1 2026 TU results before the market opens on Wednesday, May 13th. Analysts expect Innate Pharma to post earnings of ($0.3492) per share and revenue of $2.7190 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 TU earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 7:30 AM ET.

Innate Pharma (NASDAQ:IPHA – Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million during the quarter. On average, analysts expect Innate Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Innate Pharma Trading Up 0.7%

IPHA opened at $1.42 on Tuesday. Innate Pharma has a 52-week low of $1.17 and a 52-week high of $2.63. The business’s 50-day simple moving average is $1.45 and its 200 day simple moving average is $1.69.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a report on Tuesday, April 21st. BTIG Research assumed coverage on Innate Pharma in a report on Thursday, March 12th. They set a “buy” rating and a $8.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Innate Pharma in a report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Innate Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Read Our Latest Report on Innate Pharma

Institutional Trading of Innate Pharma

Several institutional investors and hedge funds have recently bought and sold shares of IPHA. Jane Street Group LLC bought a new stake in Innate Pharma in the fourth quarter valued at approximately $162,000. Millennium Management LLC bought a new stake in Innate Pharma in the fourth quarter valued at approximately $36,000. Finally, OLD Mission Capital LLC bought a new stake in Innate Pharma in the fourth quarter valued at approximately $50,000. Institutional investors own 0.16% of the company’s stock.

About Innate Pharma

(Get Free Report)

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.